Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 9/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7055717 | 0.91 | S1PR1 (0.41) | S1PR1S1PR3NPC1RAB9ALMNA | |
| SCHEMBL12372084 | 0.90 | P2RX3 (0.42) | S1PR1S1PR3RAB9AKDRLMNA | |
| SCHEMBL5779683 | 0.89 | S1PR1 (0.36) | S1PR1S1PR3NPC1RAB9AKDR | |
| SCHEMBL27608112 | 0.83 | KMT2A (0.35) | TP53 | |
| SCHEMBL4654929 | 0.82 | CAMK2D (0.37) | — | |
| SCHEMBL5663451 | 0.81 | CNR1 (0.35) | POLBLMNACHRM1 | |
| SCHEMBL5779687 | 0.80 | NPC1 (0.34) | NPC1RAB9APOLBLMNATP53 | |
| SCHEMBL8635242 | 0.78 | NPC1 (0.31) | NPC1RAB9AKDR | |
| SCHEMBL4654781 | 0.75 | P2RX3 (0.40) | — | |
| SCHEMBL5969688 | 0.75 | S1PR1 (0.40) | S1PR1S1PR3KDRPOLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7998462-B2 | Linkers for anchoring targeting ligands | KEREOS, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998462-B2 | Linkers for anchoring targeting ligands | KEREOS, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| EP-1622647-B1 | VITRONECTIN RECEPTOR ANTAGONIST COMPOUNDS AND THEIR USE IN THE PREPARATION OF RADIOPHARMACEUTICALS | LANTHEUS MEDICAL IMAGING INC (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20080305037-A1 | LINKERS FOR ANCHORING TARGETING LIGANDS | KEREOS, INC. | 2008-12-11 | — | — | US | disclosed |
| US-20080305037-A1 | LINKERS FOR ANCHORING TARGETING LIGANDS | KEREOS, INC. | 2008-12-11 | — | — | US | disclosed |
| EP-1307226-B1 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | LANTHEUS MEDICAL IMAGING INC (US) | 2008-11-19 | — | — | EP | disclosed |
| WO-2008070291-A2 | IMPROVED LINKERS FOR ANCHORING TARGETING LIGANDS | KEREOS, INC. (US) | 2008-06-12 | — | — | WO | disclosed |
| EP-1423152-A4 | SIMULTANEOUS IMAGING OF CARDIAC PERFUSION AND A VITRONECTIN RECEPTOR TARGETED IMAGING AGENT | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2006-12-27 | — | — | EP | disclosed |
| US-7138104-B2 | Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-21 | — | — | US | disclosed |
| EP-0944619-B1 | NOVEL INTEGRIN RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2006-10-11 | — | — | EP | disclosed |
| US-20020122768-A1 | Stable radiopharmaceutical compositions and methods for preparation thereof | LANTHEUS MEDICAL IMAGING, INC. | 2002-09-05 | — | — | US | disclosed |
| CN-1356913-A | vitronectin receptor antagonist drugs | DU PONT PHARM CO (US) | 2002-07-03 | — | — | CN | disclosed |
| US-20020061909-A1 | Vitronectin receptor antagonist pharmaceuticals | LANTHEUS MI REAL ESTATE, LLC | 2002-05-23 | — | — | US | disclosed |
| US-20020041878-A1 | Vitronectin receptor antagonist pharmaceuticals | LANTHEUS MEDICAL IMAGING, INC. | 2002-04-11 | — | — | US | disclosed |
| US-6358976-B1 | FOR THERAPY AND PROPHYLAXIS OF CANCER METASTASIS, DIABETIC RETINOPATHY, NEOVASCULAR GLAUCOMA, THROMBOSIS, RESTENOSIS, OSTEOPOROSIS, OR MACULAR DEGENERATION | LANTHEUS MI REAL ESTATE, LLC | 2002-03-19 | — | — | US | disclosed |
| US-20020015680-A1 | QUINOLONE VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | CITIZENS BANK, N.A. | 2002-02-07 | — | — | US | disclosed |
| WO-2001097848-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-12-27 | — | — | WO | disclosed |
| EP-1140204-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | Du Pont Pharmaceuticals Company (US) | 2001-10-10 | — | — | EP | disclosed |
| US-6130231-A | SUBSTITUTED 2,3-DIHYDROQUINOLIN-4-ONES | DUPONT PHARMACEUTICALS (US) | 2000-10-10 | — | — | US | disclosed |
| WO-2000035492-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020015680-A1 | QUINOLONE VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | ADGRF1, QRFPR, ADGRE5 | S1PR1 980/4885S1PR3 848/4885NPC1 2220/4885 |
| US-20080305037-A1 | LINKERS FOR ANCHORING TARGETING LIGANDS | LDLR, HDLBP, FABP1 | S1PR1 259/4885S1PR3 272/4885NPC1 85/4885 |
| US-20020041878-A1 | Vitronectin receptor antagonist pharmaceuticals | ADGRF1, RXFP1, VCAM1 | S1PR1 265/4885S1PR3 290/4885NPC1 2183/4885 |
| US-20020122768-A1 | Stable radiopharmaceutical compositions and methods for preparation thereof | AHR, PAH, TYR | S1PR1 915/4885S1PR3 749/4885NPC1 468/4885 |
| US-20020061909-A1 | Vitronectin receptor antagonist pharmaceuticals | ADGRF1, RXFP1, VCAM1 | S1PR1 285/4885S1PR3 309/4885NPC1 2141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.